Article
FDA staff says safety issues with Biogen's ALS drug to not prevent approval
Rating:
0.0
Views:
56
Likes:
1
Library:
1
The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value